Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/ACE inhibitors and ARBs improve ejection fraction in dilated cardiomyopathy
Hfref · ACEARB-HFREF-02 · v2
The question is whether drugs that block the renin-angiotensin system help the heart's pumping strength improve in people with dilated cardiomyopathy, a condition where the heart is enlarged and weakened. Only one study here looked at exactly that population and outcome, and it was an observational registry: patients taking these drugs more often regained pumping function than those who did not [6]. Several controlled trials in the broader population of weak-hearted heart-failure patients show that one of these drugs, enalapril, can improve pumping and reverse the heart's enlargement [1][3], which supports the underlying biology. But those trials were not done specifically in dilated cardiomyopathy, and one head-to-head trial found that enalapril did not change pumping strength while an angiotensin-receptor blocker did [5]. Because the direct evidence in the named condition is a single observational study open to the possibility that healthier patients simply received the drugs, the panel treated the claim's direction as supported but not firmly established.
In the only study matching dilated cardiomyopathy with an ejection-fraction recovery endpoint, a propensity-matched registry cohort of 830 pairs, recovery to LVEF >=40% at 3 years occurred more often with ACEi/ARB use than without (57.0% versus 49.3%; odds ratio 1.36; 95% CI 1.12-1.65; P=0.002), with a greater mean LVEF change (14.9% versus 12.3%; P=0.001) [6]. In general heart-failure populations, randomised trials support the remodelling mechanism: enalapril raised LVEF from 0.25 to 0.29 and prevented left-ventricular dilatation versus placebo [1], and reduced LV dimensions while increasing shortening fraction versus placebo [3]. An angiotensin-receptor blocker raised LVEF from 31% to 39% (P<0.001) in congestive heart failure [5]. No placebo-controlled trial in this corpus measures ejection-fraction recovery specifically within dilated cardiomyopathy. The contested point: The evidence divides on whether the direct signal is causal: the one dilated-cardiomyopathy study [6] reports only association and is exposed to confounding by indication, so healthier patients receiving the drugs could explain its recovery gap. It also divides internally, because enalapril did not significantly change ejection fraction where the angiotensin-receptor blocker did [5], unsettling the 'ACEi facilitate recovery' half of the claim.
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only paper matching DCM population and EF-recovery outcome [6] is observational and explicitly reports association; confounding by indication (healthier patients receive and tolerate ACEi/ARB) can wholly explain the 57.0% vs 49.3% recovery gap. No causal claim is licensed.
No placebo-controlled RCT of ACEi/ARB versus control measuring EF recovery specifically in DCM exists in this corpus; the causal RCT support [1][3] is in general HFrEF/CHF, an indirect extrapolation to the DCM population named in the claim.
Where it remains uncertain. The DCM-specific signal is observational and confounded by indication [6], while the causal RCT support is extrapolated from non-DCM populations and is internally mixed, since enalapril did not change EF where an ARB did [5].
Aleatory
Ejection-fraction recovery varies substantially between individuals and over time; even in the recovery group of [6] only 57.0% reached LVEF >=40%, so outcome in any one patient is not determined by treatment.
Epistemic
The corpus contains no placebo-controlled RCT measuring EF recovery in dilated cardiomyopathy; the only on-population study [6] is observational, leaving the causal question unresolved by better-designed evidence.
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Randomised evidence that ACEi raises LVEF vs placebo in HFrEF, supporting the mechanism.
“Mean LVEF increased in enalapril patients from 0.25 +/- 0.07 to 0.29 +/- 0.08 (p less than 0.01).”
Panel auditInternal validity: medium · scope of inference: Patients with mild-to-moderate symptomatic heart failure and depressed EF of mixed etiology, treated with an ACE inhibitor.Key limitations: not dilated-cardiomyopathy specific · small imaging substudy · mixed heart failure etiology
Randomised placebo-controlled evidence of improved systolic function with ACEi.
“Echocardiographic left ventricular dimensions were significantly reduced and left ventricular shortening fraction significantly increased in the enalapril group but were unchanged in the placebo group.”
Panel auditInternal validity: medium · scope of inference: NYHA II-III chronic heart failure patients stable on digoxin and diuretics, measured by shortening fraction.Key limitations: shortening fraction reported, not ejection fraction · not dilated-cardiomyopathy specific · very small sample · short 3-month follow-up
ARB raised LVEF in CHF, but enalapril did not here — partially discordant for the ACEi half of the claim.
“LVEDV decreased from 172 (42) ml to 151 (45) ml (p < 0.05) and LVEF increased from 31 (7)% to 39 (10)% (p < 0.001). However, these parameters did not change significantly in patients receiving enalapril.”
Panel auditInternal validity: low · scope of inference: Congestive heart failure patients with LVEF <40%, comparing an ARB to an ACEi over six months.Key limitations: no untreated/placebo arm · within-group change inference · not dilated-cardiomyopathy specific · small sample
3 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The claim's direction is supported but rests on one observational DCM study plus indirect RCT mechanism evidence that is internally mixed, which does not carry a higher tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomised DCM EF-recovery trial. The claim names dilated cardiomyopathy, yet the only direct evidence [6] is observational; causation cannot be separated from confounding by indication. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A placebo-controlled randomised trial of ACEi or ARB versus control in LVEF<40% dilated cardiomyopathy with a pre-specified EF-recovery endpoint.
Open question: Does ACEi or ARB versus control cause ejection-fraction recovery in dilated cardiomyopathy specifically? Why it is still open: The only DCM study [6] is a propensity-matched observational cohort reporting association, and no placebo-controlled DCM trial exists in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19